Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
NRW Holdings Shares Surge After Securing Major Rio Tinto Contract and New Project Wins 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
(4) - EconoTimes)
CAMBRIDGE, Mass., May 31, 2017 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases, granted equity awards on May 31, 2017, that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to ten individuals hired by Sarepta in May 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 57,820 shares of Sarepta's common stock. The options have an exercise price of $29.84 per share, which is equal to the closing price of Sarepta's common stock on May 31, 2017. One-fourth of the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 [email protected] or W2O Group Brian Reid, 212-257-6725 [email protected]
